You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Toripalimab

Showing 26 - 50 of 351
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rectal Cancer Trial in Chengdu (drug, radiation, procedure)

Recruiting
  • Rectal Cancer
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Mar 8, 2023

Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Recruiting
  • Lung Cancer
  • Toripalimab
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Dec 7, 2022

Locally Advanced Head and Neck Squamous Cell Carcinoma Trial (Toripalimab)

Not yet recruiting
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Toripalimab
  • (no location specified)
Mar 20, 2023

Locally Advanced, High-Risk, Rectal Cancer Trial in Guangzhou (Toripalimab, short-term radiotherapy, Oxaliplatin)

Not yet recruiting
  • Locally Advanced
  • +3 more
  • Toripalimab
  • +3 more
  • Guangzhou, Guangdong, China
    Nanfang Hospital Southern Medical University
May 17, 2023

Urinary Bladder Cancer Trial in Guangzhou (Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin)

Recruiting
  • Urinary Bladder Cancer
  • Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
  • Guangzhou, Guangdong, China
    Zhujiang Hospital
Jan 6, 2023

Oral Squamous Cell Carcinoma Trial in Beijing (Toripalimab)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • Toripalimab
  • Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 5, 2023

Nasopharyngeal Carcinoma Trial in Xi'an (gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • gemcitabine,nimotuzumab, toripalimab
  • gemcitabine, cisplatin
  • Xi'an, Shaanxi, China
    Department of Radiation Oncology, Xijing Hospital, Fourth Milita
Sep 5, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial in Shanghai (Endostar,

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 17, 2023

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

NSCLC Trial in Beijing (RC108)

Not yet recruiting
  • NSCLC
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 18, 2023

Gestational Trophoblastic Neoplasia Trial in Beijing (Toripalimab, Actinomycin-D)

Not yet recruiting
  • Gestational Trophoblastic Neoplasia
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 1, 2023

Advanced Nasopharyngeal Carcinoma Trial in Guangzhou (Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • Toripalimab injection(subcutaneous)/JS001sc
  • Toripalimab /JS001
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 21, 2023

Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)

Recruiting
  • Esophageal Squamous Cell Cancer
  • Toripalimab
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023

Gestational Trophoblastic Neoplasia Trial in Beijing (Toripalimab, Actinomycin-D)

Not yet recruiting
  • Gestational Trophoblastic Neoplasia
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 7, 2023

Advanced Pancreatic Cancer Trial in Shanghai (Pimicotinib (ABSK021))

Recruiting
  • Advanced Pancreatic Cancer
  • Pimicotinib (ABSK021)
  • Shanghai, Shanghai, China
    Renji Hospital Affiliated to Shanghai Jiaotong University School
Oct 26, 2023

Advanced Pancreatic Cancer Trial in Shanghai (CT-707, Toripalimab, Gemcitabine)

Recruiting
  • Advanced Pancreatic Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 17, 2022

Esophageal Cancer, Radiation Therapy, Immunotherapy Trial in Taizhou (Toripalimab, Tegafur, IMRT)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Toripalimab
  • +2 more
  • Taizhou, Zhejiang, China
  • +1 more
Apr 15, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency Trial in China

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Toripalimab
  • +2 more
  • Hangzhou, Zhejiang, China
  • +7 more
Feb 7, 2023

Metastatic Nasopharyngeal Carcinoma Trial (Capecitabine plus toripalimab)

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Capecitabine plus toripalimab
  • (no location specified)
Jul 30, 2022

Unresectable Hepatocellular Carcinoma Trial in Changsha (Donafenib Tosilate Tablets, Toripalimab Injection)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Donafenib Tosilate Tablets
  • Toripalimab Injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Nov 28, 2022

Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)

Not yet recruiting
  • Stage III Non-small Cell Lung Cancer
  • Toripalimab
  • +5 more
  • (no location specified)
Jun 3, 2023

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Disitamab Vedotin
  • Toripalimab
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Melanoma Trial (Chidamide combined with Toripalimab)

Not yet recruiting
  • Melanoma
  • Chidamide combined with Toripalimab
  • (no location specified)
Jul 27, 2022

Hypopharyngeal Cancer Trial (Cisplatin/Nedaplatin, albumin paclitaxel)

Not yet recruiting
  • Hypopharyngeal Cancer
  • Cisplatin/Nedaplatin, albumin paclitaxel
  • (no location specified)
May 5, 2023

NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Guangzhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2022